 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The company recently closed its acquisition of Horizon Therapeutics...

Is Amgen Stock a Buy Now?

StockNews.com assumed coverage on shares of Horizon Therapeutics Public (NASDAQ:HZNP  Free Report) in a research report released on Thursday morning. The brokerage issued a strong-buy rating...

Horizon Therapeutics Public (NASDAQ:HZNP) Earns Strong-Buy Rating from Analysts at StockNews.com

HZNP's total volume now sits at 18.4M. The +0.06% average daily price change was insignificant these 2 days, leaving HZNP's price at $116.3...

The volume for Horizon Therapeutics Public stock increased for two consecutive days, resulting in a record-breaking daily growth of 379% of the 65-Day Volume Moving Average

Amgen completes $27.8B acquisition of Horizon Therapeutics...

Amgen completes $27.8B acquisition of Horizon Therapeutics

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Horizon Therapeutics announces acquisition by Amgen approved in Ireland

Thursday's approval of a takeover scheme of arrangement is the last remaining clearance for the acquisition...

High Court paves way for Amgen's  26.4bn takeover of Irish-based Horizon Therapeutics

Horizon Therapeutics plc (NASDAQ: HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR...

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis...

Horizon Therapeutics plc Announces New UPLIZNA (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023

Cannon Global Investment Management LLC purchased a new position in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP  Free Report) during the second quarter, according to its most...

Cannon Global Investment Management LLC Invests $1.39 Million in Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Horizon Therapeutics announces new data on TEPEZZA treatment

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Watchers	6,205
52-Wk Low	$61.93
52-Wk High	$116.38

Market Cap	$26.68B
52-Wk High	$116.38
52-Wk Low	$61.93

HZNP Horizon Therapeutics Plc

About

Feed

News

Earnings

Fundamentals